cet

Hafnias Q3 2025 Financial Results Presentation to Be Held on 1 December 2025

SINGAPORE--(BUSINESS WIRE)--Hafnia Limited (“Hafnia”, the “Company”, OSE ticker code: “HAFNI”, NYSE ticker code “HAFN”) will release its Q3 2025 results…

4 days ago

Milano Cortina 2026 Olympic FlameLighting and Handover Ceremonies Information for the Media

22 October 2025 - On Wednesday 26 November 2025 at 11:00 CET, the Olympic flame for the Milano Cortina 2026 Olympic…

1 month ago

NTG Nordic Transport Group A/S – Q3 2025 Conference Call

October 10, 2025 04:00 ET  | Source: NTG Nordic Transport Group A/S NTG Nordic Transport Group A/S – Q3 2025…

2 months ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led…

2 months ago

Publication relating to transparency notifications

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025, 10:30 pm CET / 4:30 pm ET –…

2 months ago

ASM hosts Investor Day, provides new 2030 targets, revises H2 2025 outlook

Almere, The Netherlands September 23, 2025, 7:45 a.m. CET ASM International N.V. (Euronext Amsterdam: ASM) today hosts its 2025 Investor…

2 months ago

OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders Annual General Meeting of September 30, 2025

OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025 NANTES, France, September…

3 months ago

ZETADISPLAY AB (publ) INTERIM REPORT 1 APRIL 30 JUNE 2025 (Q2)

Q2 Interim report April – June 2025 for ZetaDisplay AB (publ) is now published at the ZetaDisplay Investor relations web:…

3 months ago

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies…

3 months ago

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today…

4 months ago